Loading...
•
Dec 31, 2022
Recursion Pharmaceuticals Q4 2022 Earnings Report
Recursion Pharmaceuticals reported business updates and financial results
Key Takeaways
Recursion Pharmaceuticals reported a revenue of $13.7 million for the fourth quarter of 2022, compared to $2.5 million for the fourth quarter of 2021. Net loss was $57.5 million for the fourth quarter of 2022, compared to a net loss of $64.9 million for the fourth quarter of 2021.
Initiated five clinical trials in 2022, including three Phase 2 programs, and provided guidance on the timing of clinical data readouts.
Delivered against core elements of Roche-Genentech collaboration and Bayer collaboration in 2022.
Continued to build-out the Recursion OS with scaled transcriptomic technologies, industry-leading hiPSC-derived cell production, and additional in-house chemistry capabilities.
Released RXRX3 and MolRec™.
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Recursion Pharmaceuticals Revenue by Segment
Revenue by Segment
Collaborative agreements Revenue
CapyFin.com Forward Guidance
This document contains information that includes or is based upon 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; the timing of data from our studies or initiating IND studies; licenses and collaborations, including whether additional partnerships are entered into, existing partner options are exercised and the timing of such exercises; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; the release of an updated ESG report; and all other statements that are not historical facts.